TY - JOUR
T1 - Antifungal prophylaxis in lung transplantation
AU - Avery, Robin K.
N1 - Funding Information:
Competing interests : COM has sat on advisory boards for, received investigator-initiated grant support from and given lectures for Gilead Sciences, Pfizer, Merck, Schering-Plough and Orphan Australia; DCMK has sat on advisory boards for Pfizer and receives financial support from Pfizer, Roche, Novartis, Merck and Gilead Sciences. All other authors declare no competing interests.
PY - 2011
Y1 - 2011
N2 - Fungal infections are among the most serious complications of lung transplantation. The 1-year cumulative incidence of invasive fungal infections in lung transplant recipients is 6 to 10%, which is higher than most other solid organ transplant recipients. Aspergillus spp. are the most common etiologic agents, but Candida spp., non-Aspergillus mycelial fungi, Cryptococcus, Pneumocystis, and endemic mycoses can cause active infections in this population. Clinical manifestations of fungal infection in lung transplant recipients are protean, and include invasive pulmonary disease, airway and anastomotic infections, posttransplant empyemas, and disseminated infections. Most centers employ either universal or targeted antifungal prophylaxis in some form, but the agents, doses, durations, and monitoring strategies vary widely from one center to another. This review discusses the salient fungal organisms responsible for infection in lung transplant recipients and management strategies for prevention.
AB - Fungal infections are among the most serious complications of lung transplantation. The 1-year cumulative incidence of invasive fungal infections in lung transplant recipients is 6 to 10%, which is higher than most other solid organ transplant recipients. Aspergillus spp. are the most common etiologic agents, but Candida spp., non-Aspergillus mycelial fungi, Cryptococcus, Pneumocystis, and endemic mycoses can cause active infections in this population. Clinical manifestations of fungal infection in lung transplant recipients are protean, and include invasive pulmonary disease, airway and anastomotic infections, posttransplant empyemas, and disseminated infections. Most centers employ either universal or targeted antifungal prophylaxis in some form, but the agents, doses, durations, and monitoring strategies vary widely from one center to another. This review discusses the salient fungal organisms responsible for infection in lung transplant recipients and management strategies for prevention.
KW - Fungal prophylaxis
KW - aspergillosis
KW - invasive fungal infections
KW - lung transplant
KW - mold infection
UR - http://www.scopus.com/inward/record.url?scp=83655191221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83655191221&partnerID=8YFLogxK
U2 - 10.1055/s-0031-1295719
DO - 10.1055/s-0031-1295719
M3 - Article
C2 - 22167399
AN - SCOPUS:83655191221
SN - 1069-3424
VL - 32
SP - 717
EP - 726
JO - Seminars in Respiratory and Critical Care Medicine
JF - Seminars in Respiratory and Critical Care Medicine
IS - 6
ER -